| Genomic hallmarks and structural variation in metastatic prostate cancer DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ... Cell 174 (3), 758-769. e9, 2018 | 688 | 2018 |
| Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer AA Azad, SV Volik, AW Wyatt, A Haegert, S Le Bihan, RH Bell, ... Clinical cancer research 21 (10), 2315-2324, 2015 | 528 | 2015 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 487 | 2018 |
| High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development D Lin, AW Wyatt, H Xue, Y Wang, X Dong, A Haegert, R Wu, S Brahmbhatt, ... Cancer research 74 (4), 1272-1283, 2014 | 407 | 2014 |
| Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ... JNCI: Journal of the National Cancer Institute 109 (12), djx118, 2017 | 401 | 2017 |
| Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ... JAMA oncology 2 (12), 1598-1606, 2016 | 376 | 2016 |
| The master neural transcription factor BRN2 is an androgen receptor–suppressed driver of neuroendocrine differentiation in prostate cancer JL Bishop, D Thaper, S Vahid, A Davies, K Ketola, H Kuruma, R Jama, ... Cancer discovery 7 (1), 54-71, 2017 | 371 | 2017 |
| Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 … DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ... The Lancet Oncology 20 (12), 1730-1739, 2019 | 316 | 2019 |
| Mutations in BMP4 cause eye, brain, and digit developmental anomalies: overlap between the BMP4 and hedgehog signaling pathways P Bakrania, M Efthymiou, JC Klein, A Salt, DJ Bunyan, A Wyatt, ... The American Journal of Human Genetics 82 (2), 304-319, 2008 | 300 | 2008 |
| The placental gene PEG10 promotes progression of neuroendocrine prostate cancer S Akamatsu, AW Wyatt, D Lin, S Lysakowski, F Zhang, S Kim, C Tse, ... Cell reports 12 (6), 922-936, 2015 | 273 | 2015 |
| Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors D Quigley, JJ Alumkal, AW Wyatt, V Kothari, A Foye, P Lloyd, R Aggarwal, ... Cancer discovery 7 (9), 999-1005, 2017 | 272 | 2017 |
| The DNA methylation landscape of advanced prostate cancer SG Zhao, WS Chen, H Li, A Foye, M Zhang, M Sjöström, R Aggarwal, ... Nature genetics 52 (8), 778-789, 2020 | 259 | 2020 |
| Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients N Lallous, SV Volik, S Awrey, E Leblanc, R Tse, J Murillo, K Singh, ... Genome biology 17, 1-15, 2016 | 242 | 2016 |
| Treatment outcomes and tumor loss of heterozygosity in germline DNA repair–deficient prostate cancer M Annala, WJ Struss, EW Warner, K Beja, G Vandekerkhove, A Wong, ... European urology 72 (1), 34-42, 2017 | 227 | 2017 |
| From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer AV Lapuk, C Wu, AW Wyatt, A McPherson, BJ McConeghy, S Brahmbhatt, ... The Journal of pathology 227 (3), 286-297, 2012 | 218 | 2012 |
| Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ... European urology 75 (4), 667-675, 2019 | 182 | 2019 |
| Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ... Clinical cancer research 23 (21), 6487-6497, 2017 | 158 | 2017 |
| Targeting the adaptive molecular landscape of castration‐resistant prostate cancer AW Wyatt, ME Gleave EMBO molecular medicine 7 (7), 878-894, 2015 | 158 | 2015 |
| Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth Y Yamamoto, Y Loriot, E Beraldi, F Zhang, AW Wyatt, NA Nakouzi, F Mo, ... Clinical cancer research 21 (7), 1675-1687, 2015 | 132 | 2015 |
| Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials MP Deek, K Van der Eecken, P Sutera, RA Deek, V Fonteyne, AA Mendes, ... Journal of clinical oncology 40 (29), 3377-3382, 2022 | 129 | 2022 |
Kim N. ChiProfessor of Medicine, University of British ColumbiaVerified email at bccancer.bc.ca
